Clinical Opiate Withdrawal Scale (COWS)
A Pivot Protocols Clinical Reference
The instrument isn't wrong. It's measuring the wrong patient.
The Clinical Opiate Withdrawal Scale — COWS — is one of the most important tools in addiction medicine. It has helped thousands of providers make safe induction decisions. It is well designed, well validated, and widely used for good reason.
This page isn't an argument against COWS.
It's an argument that COWS was built for a specific patient — and that applying it unchanged to a different patient produces a systematic failure that falls entirely on the person seeking help.
Understanding what COWS measures, why it measures it that way, and where its design boundary sits is essential for anyone navigating buprenorphine induction from kratom or 7-OH dependence — as a patient or as a provider.
What COWS is and what it does
COWS scores eleven observable signs and symptoms of opioid withdrawal. Each item is rated on a severity scale. The scores are added together to produce a total that tells the clinician how far into withdrawal the patient is — and whether it's safe to proceed with buprenorphine induction.
The instrument was developed and validated by Wesson and Ling, published in the Journal of Psychoactive Drugs in 2003, specifically for full agonist opioid withdrawal assessment. It remains the standard clinical instrument for this purpose.
The standard threshold for proceeding with induction is a score of 8 or higher. SAMHSA's Treatment Improvement Protocol 63 recommends a threshold of 12. Below threshold — standard protocol holds: wait longer, let withdrawal deepen.
In plain terms: COWS answers one question — has enough of the previous opioid cleared the system for buprenorphine to be introduced safely? For the population it was designed for, it answers that question accurately.
The eleven items
Here's what COWS scores and how:
Resting pulse rate — measured after the patient has been sitting for one minute. A pulse of 80 or below scores 0. Above 120 scores 4.
Sweating — observed over the prior 30 minutes, not attributed to room temperature. No report of chills or flushing scores 0. Sweat streaming off the face scores 4.
Restlessness — observed during the assessment. Able to sit still scores 0. Unable to sit still for more than a few seconds scores 5.
Pupil size — compared to expected size for room lighting. Normal or pinned scores 0. Pupils so dilated only the rim of the iris is visible scores 5.
Bone or joint aches — only the component attributed to withdrawal, not pre-existing pain. Not present scores 0. Unable to sit still due to discomfort scores 4.
Runny nose or tearing — not attributed to cold or allergies. Not present scores 0. Tears streaming down cheeks or nose constantly running scores 4.
Gastrointestinal upset — over the prior 30 minutes. No symptoms scores 0. Multiple episodes of vomiting or diarrhea scores 5.
Tremor — observed in outstretched hands. No tremor scores 0. Gross tremor or muscle twitching scores 4.
Yawning — observed during the assessment. No yawning scores 0. Yawning several times per minute scores 4.
Anxiety or irritability — patient report and observation. None scores 0. So irritable or anxious that participation in the assessment is difficult scores 4.
Gooseflesh skin — skin is smooth scores 0. Prominent piloerection scores 5.
How the total is interpreted: 5–12 is mild withdrawal. 13–24 is moderate. 25–36 is moderately severe. Above 36 is severe.
Why COWS was built this way
The items COWS weights most heavily — gastrointestinal disturbance, pupil dilation, tremor, gooseflesh — are the beta-arrestin mediated somatic symptoms of full agonist opioid withdrawal.
Full agonists — heroin, fentanyl, oxycodone, morphine — activate the mu-opioid receptor through two signaling pathways simultaneously. The beta-arrestin pathway drives the severe GI picture, profuse sweating, tremor, and pupil dilation that define classical opioid withdrawal at 12 to 24 hours post-dose. That picture is observable, scoreable, and reliably present in the population COWS was designed to assess.
The threshold of 8 was calibrated against that arc. At that score, enough of the full agonist has cleared that buprenorphine can displace it without triggering the dramatic receptor activation drop that causes precipitated withdrawal. The logic is pharmacologically sound — for that patient, at that point on that withdrawal arc.
What that means: COWS is accurate. It was just built for a different pharmacology than kratom and 7-OH produce.
The pharmacological distinction that matters here: Partial Agonist vs Full Agonist Opioids
Where COWS falls short for this population
Kratom alkaloids and 7-OH are G-protein biased partial mu-opioid receptor agonists. They activate the receptor primarily through the G-protein pathway with substantially less beta-arrestin recruitment than classical full agonist opioids.
That pharmacological difference changes the withdrawal picture in two ways that COWS was not designed to capture.
The physical gap:
The symptoms COWS weights most heavily — significant gastrointestinal disturbance, tremor, yawning, significant pupil dilation — are largely absent in the early descending activation window that represents the optimal induction opportunity for this population.
They are not absent from the withdrawal picture entirely. With extended abstinence — 12 to 24 hours — they would likely emerge. But in a compression cycle pattern dosing every two to three hours, extended abstinence is exactly what the cycle prevents. The induction window opens and closes within two to three hours of the last dose — before the GI picture has time to develop. COWS was calibrated for a withdrawal arc that takes 12 to 24 hours to reach threshold. This population's induction window closes before that arc can form.
The symptoms that are present — elevated heart rate, episodic heat flashes and sweating, sneezing clusters, anxiety, restlessness — score lower on the instrument's weighting.
The emotional gap:
This is the dimension COWS doesn't capture at all.
The mu-opioid system is a primary regulator of emotional tone, grief processing, and the nervous system's capacity to buffer difficult emotional material. When kratom alkaloids or 7-OH clear every two to three hours, the emotional regulatory function clears with them. Depression, waves of grief, dysphoria, a profound sense of loss — all arriving on the dosing schedule, all resolving when the dose lands.
None of this appears on COWS. The emotional dimension of withdrawal in this population is entirely outside the instrument's measurement architecture.
The full withdrawal picture this population presents — physical and emotional — is documented here: G-protein Biased Autonomic Dysregulation
The compression cycle pattern that produces it: Compressed-Cycle Opioid Dependence
In plain terms: a person in significant withdrawal distress — autonomic signals running, emotional regulatory system cycling through depression and dysphoria every two to three hours — may score a 3 or 4 on COWS. Well below the standard threshold of 8. The instrument isn't wrong. It's measuring a different patient.
The cost of the mismatch
When a provider applies standard COWS-based induction timing to a person in a compression cycle pattern the clinical instruction that follows is to wait. The score doesn't support proceeding. The protocol is being followed correctly.
But the patient is already in withdrawal by every measure their nervous system is producing. The autonomic signals are running. The emotional regulatory system is cycling. The induction window is open and narrowing.
They are told to wait longer.
Two things can happen from here.
The redosing compulsion wins before the COWS score reaches threshold. The person doses again. The cycle resets. The treatment window closes. They leave having tried to access help and been unable to get through the door — not because they lacked commitment but because the clinical process asked them to endure a waiting period calibrated for a different pharmacological arc.
Or they endure. They white-knuckle through deepening autonomic and emotional distress — distress that correctly timed induction would have prevented — eventually reaching a score that satisfies the threshold. They proceed with induction having suffered more than was necessary, with their trust in the treatment process damaged before it began.
Either outcome represents a clinical failure that standard protocol, applied correctly to the wrong population, produces reliably.
This is not a criticism of providers. It is a description of what happens when a well-designed instrument is applied beyond its design boundary without adjustment.
The largest published case series on buprenorphine induction from kratom dependence — Broyan, Brar, Allgaier et al., Substance Abuse, 2022 — found zero cases of precipitated withdrawal across 28 patients. This finding is consistent with the partial-to-partial transition dynamics the pharmacology predicts — and suggests the caution that drives extended waiting periods may be overcalibrated for this population.
What to use alongside COWS
COWS remains a useful starting point. The adjustments for this population are additions, not replacements.
Weight patient self-report heavily. A patient reporting significant withdrawal pressure — mounting anxiety, heat flashes, restlessness, building urgency — who scores below the standard COWS threshold is not necessarily outside the optimal induction window. Their reported experience may be more diagnostically accurate than the scored instrument in this context.
Attend to the autonomic signal cluster. Elevated resting heart rate, warm episodic sweating, heat flashes, sneezing clusters, anxiety, and restlessness — present in a patient with a documented compression cycle pattern — represent clinically meaningful evidence of the descending activation window regardless of COWS score.
Consider the compression cycle timeline. A patient dosing multiple times daily is not on a 12 to 24 hour clearance arc. Their optimal induction window may open within two to three hours of their last dose.
Account for the emotional dimension. Depression, dysphoria, and waves of grief arriving on the dosing schedule and resolving with the dose are withdrawal symptoms — not a separate mental health presentation. They belong in the clinical picture even though they don't appear on COWS.
Understand the partial-to-partial transition. The precipitated withdrawal risk in a kratom or 7-OH to buprenorphine transition is pharmacologically distinct from a full agonist transition. Standard caution remains appropriate. The fear that drives extended waiting periods appropriate for high-dose full agonist patients may be overcautious here.
The correct timing signal for this population: Activation Slope Induction
The intervention built around that signal: Pharmacologic Cycle Overwrite
What this page claims and what it does not
This page does not argue that COWS should not be used with this population. It argues that its threshold should not be applied without clinical adjustment for a patient whose pharmacological starting point differs from the one the instrument was designed to assess.
The clinical adjustments described here are grounded in established receptor pharmacology and consistent with the available literature on buprenorphine use in kratom-dependent populations. They have not been validated in a formal clinical study. They are offered as a framework for clinical reasoning — not as a replacement for clinical judgment.
The exit this framework points toward: How the Kinetic Exit Works
If this pattern sounds familiar — this takes 30 seconds. No email required.
Build Your Quit Plan
For clinicians and researchers: The COWS gap described on this page reflects a timing and calibration issue specific to the HFO/CCOD population — not a flaw in the instrument itself. COWS was designed and validated for full agonist withdrawal with a 12–24 hour arc. The relevant window in this population closes in 2–3 hours. The emotional dimension of GBAD doesn't appear on the scale at all. The terminology is new. The mechanisms are not. For Professionals →
This framework is offered for educational purposes only. All clinical decisions are made solely between the patient and their licensed medical provider.
John Leonard is the founder of Pivot Protocols and a recovery program leader with 23 years of front-line experience. The frameworks on this site were developed through direct observation, pattern recognition, and grounding in published pharmacological research. He is not a clinician or medical provider.